Capecitabine (XEL) and Mitomycin-C (MMC) used concurrently with accelerated concomitant boost radiation therapy (CB-RT) in head and neck cancer (SCCHN): Preliminary results of a phase I clinical trial

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 5595-5595
Author(s):  
B. G. Haffty ◽  
A. Psyrri ◽  
J. K. Joe ◽  
D. Slater ◽  
W. Zaheer ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Phase I ◽  
Head And Neck ◽  
Mitomycin C ◽  
Neck Cancer ◽  
Preliminary Results ◽  
Concomitant Boost ◽  
Boost Radiation

Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin

2012 ◽  
Vol 15 (4) ◽  
pp. 321-326 ◽  
Author(s):  
Jaime Gómez-Millán ◽  
Maria Dolores Toledo ◽  
Yolanda Lupiañez ◽  
Antonio Rueda ◽  
Jose Manuel Trigo ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Causes Of Death ◽  
Advanced Head ◽  
Concomitant Boost ◽  
Competing Causes ◽  
Boost Radiation ◽  
Weekly Cisplatin

scholarly journals Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial

2019 ◽  
Vol 28 (1) ◽  
pp. 261-269 ◽  
Author(s):  
G. Brandon Gunn ◽  
Tito R. Mendoza ◽  
Adam S. Garden ◽  
Xin Shelley Wang ◽  
Qiuling Shi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Randomized Clinical Trial ◽  
Neck Cancer ◽  
Symptom Reduction

Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial

2013 ◽  
Vol 107 (3) ◽  
pp. 310-316 ◽  
Author(s):  
Dieter Berwouts ◽  
Luiza A.M. Olteanu ◽  
Fréderic Duprez ◽  
Tom Vercauteren ◽  
Werner De Gersem ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Head And Neck Cancer ◽  
Phase I ◽  
Head And Neck ◽  
Neck Cancer ◽  
Phase I Clinical Trial ◽  
Dose Painting ◽  
Three Phase ◽  
Initial Results

Phase I Trial of Gefitinib in Combination With Radiation or Chemoradiation for Patients With Locally Advanced Squamous Cell Head and Neck Cancer

2007 ◽  
Vol 25 (31) ◽  
pp. 4880-4886 ◽  
Author(s):  
Changhu Chen ◽  
Madeleine Kane ◽  
John Song ◽  
John Campana ◽  
Adam Raben ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
Intermediate Stage ◽  
Concomitant Boost ◽  
Grade 3 ◽  
Boost Radiation

PurposeTo establish the safety and toxicity profile of daily gefitinib with radiation alone or with concurrent chemoradiotherapy in previously untreated patients with locally advanced squamous cell head and neck cancer (LAHNC).Patients and MethodsPatients with intermediate-stage LAHNC were treated with concomitant boost radiation (RT) alone with escalating doses of daily gefitinib (250 or 500 mg; cohort I). Once a safety profile was determined with RT alone, patients with high-risk disease were then treated with daily gefitinib (250 or 500 mg), weekly cisplatin (CDDP; 30 mg/m2), and once-daily RT (cohort II). Patients also received post-RT gefitinib at 250 mg daily for a period of up to 2 years.ResultsTwenty-three patients were enrolled and assessable for toxicity. No dose-limiting toxicities (DLTs) were observed in patients treated in cohort I at either 250 or 500 mg of gefitinib daily with concomitant boost RT to 72 Gy. In patients receiving chemoradiotherapy and gefitinib (cohort II), DLTs included one grade 4 diarrhea and one grade 4 neutropenic fever. Fifteen patients started maintenance gefitinib, and eight (53%) experienced grade 1 to 2 acne-like skin rash and diarrhea, but no grade 3 or 4 toxicity occurred.ConclusionGefitinib (250 or 500 mg daily) was well tolerated with concomitant boost RT or concurrent chemoradiotherapy with weekly CDDP. Protracted administration of gefitinib for up to 2 years at 250 mg daily was also tolerated well.

Sign in / Sign up

Export Citation Format

Share Document